Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 211

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 211
---
 Combination will be treated as the equivalent of Liminatus issuing stock for the net assets of Iris, accompanied by a recapitalization. The net assets of Iris will be stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination will be those of Liminatus.

The unaudited pro forma combined balance sheet as of September 30, 2024 gives pro forma effect to the Business Combination and other events contemplated by the Business Combination Agreement as if they had been consummated on September 30, 2024. The unaudited pro forma combined statement of operations for the nine months ended September 30, 2024 and year ended December 31, 2023 give pro forma effect to the Business Combination and the other events contemplated by the Business Combination Agreement as if they had been consummated on January 1, 2023.

The unaudited pro forma combined balance sheet as of September 30, 2024 and unaudited pro forma combined statement of operations for the nine months ended September 30, 2024 have been derived from and should be read in conjunction with the following:

•

the historical unaudited financial statements of Iris as of September 30, 2024 and for the nine months ended September 30, 2024 and the related notes, which are included in the Iris September 2024 10-Q, which are included elsewhere in this proxy statement/prospectus; and

•

the historical unaudited financial statements of Liminatus as of September 30, 2024 and for the nine months ended September 30, 2024 and the related notes, which are included elsewhere in this proxy statement/ prospectus.

The unaudited pro forma combined statement of operations as of and for the year ended December 31, 2023 have been derived from and should be read in conjunction with the following:

•

the historical audited financial statements of Iris as of and for the year ended December 31, 2023 and the related notes, which are included in the Iris 2023 10-K, which are included elsewhere in this proxy statement/prospectus; and

•

the historical audited financial statements of Liminatus as of and for the year ended December 31, 2023 and the related notes, which are included elsewhere in this proxy statement/prospectus.

The unaudited pro forma combined financial information should also be read together with the sections of the Iris September 2024